Joint Formulary & PAD

Rifaximin 550mg tablets - Hepatic encephalopathy

You are here : Home > Formulary Search > Rifaximin 550mg tablets - Hepatic encephalopathy

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
R
SPC
Restrictions / Comments :
Important
Restricted use on recommendation of Gastroenterology consultants for treatment of hepatic encephalopathy.

Documentation

Guidelines (Local)
Rifaximin for Overt Hepatic Encephalopathy -Treatment Pathway - Aug 2021.pdf
NICE Technology Appraisal
NICE TA337 - Rifaximin for prevention of Hepatic Encephalopathy

PAD Profile

ChemicalSubstance :
Rifaximin 550mg tablets
Indication :
Hepatic encephalopathy
Group Name :
Keywords :
NICE, AMBER, Shared Care, antibiotic, antibacterial
Brand Names Include :
Targaxan
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

04 Aug 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that rifaximin for the reduction in  recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age, has a BLUE (with flow chart/pathway) traffic light status. See below for agreed documentation

Other Indications

Below are listed other indications that Rifaximin 550mg tablets is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Hepatic encephalopathy.